Zimmer Biomet (ZBH) Stock Price, News & Analysis

Company Overview

Zimmer Biomet Holdings, Inc. is a global leader in musculoskeletal healthcare, specializing in the design, manufacture and marketing of orthopaedic reconstructive products, including joint replacement implants and related surgical instruments. The company’s product portfolio spans hip and knee replacements, shoulder and elbow implants, spinal and trauma devices, sports medicine solutions and dental reconstructive products. Zimmer Biomet also offers biologics, surgical power tools and digital solutions aimed at improving patient outcomes and supporting healthcare professionals throughout the continuum of care.

Tracing its roots to the founding of Zimmer in Warsaw, Indiana in 1927 and Biomet in Warsaw, Indiana in 1977, the combined Zimmer Biomet entity emerged in 2015 following the merger of the two companies. Over nearly a century, the company has built a reputation for innovation in orthopaedics, introducing new biomaterials and advanced manufacturing techniques. Today, Bryan C. Hanson serves as President and Chief Executive Officer, leading a management team focused on operational excellence, research and development, and strategic growth initiatives.

Zimmer Biomet’s core business activities center on developing and commercializing advanced orthopaedic solutions for joint reconstruction, spinal care, trauma management and dental applications. Its reconstruction portfolio features a range of knee systems, hip systems and shoulder implants engineered to restore mobility and relieve pain. In the spine and trauma segment, the company offers fixation systems, biologic products and minimally invasive surgical solutions. Complementing its implant offerings, Zimmer Biomet provides comprehensive surgical instruments, robotic-assisted technologies and pre- and post-operative digital planning tools.

With operations in more than 25 countries and product distribution in over 100 markets, Zimmer Biomet serves surgeons, hospitals and dental practices worldwide. Manufacturing facilities span North America, Europe and Asia, supported by a global sales and marketing network. The company invests in collaborative research partnerships and educational programs aimed at advancing musculoskeletal health and providing training for healthcare professionals. Through this extensive reach and ongoing innovation, Zimmer Biomet remains committed to enhancing patient quality of life and driving progress in orthopaedic care.

Key Stats

• Today's Range: $99.14 to $101.65
• 50-Day Range: $90.63 to $107.64
• 52-Week Range: $89.22 to $114.72
• Volume: 879,318 shs
• Average Volume: 1.97 million shs
• Market Capitalization: $19.92 billion
• P/E Ratio: 24.43
• Dividend Yield: 0.95%
• Price Target: $111.00
• Consensus Rating: Hold

Zimmer Biomet Stock Analysis - MarketRank™

Zimmer Biomet scored higher than 96% of companies evaluated by MarketBeat, and ranked 47th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Zimmer Biomet has received a consensus rating of Hold. The company's average rating score is 2.39, and is based on 9 buy ratings, 7 hold ratings, and 2 sell ratings.

Upside Potential

Zimmer Biomet has a consensus price target of $111.00, representing about 10.7% upside from its current price of $100.31.

Amount of Analyst Coverage

Zimmer Biomet has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 7.91%

Earnings Growth

Earnings for Zimmer Biomet are expected to grow by 7.91% in the coming year, from $8.22 to $8.87 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zimmer Biomet is 24.40, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 281.30.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zimmer Biomet is 24.40, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 76.58.

Price to Earnings Growth Ratio

Zimmer Biomet has a PEG Ratio of 2.32. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Zimmer Biomet has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.94% of the float of Zimmer Biomet has been sold short.

Short Interest Ratio / Days to Cover

Zimmer Biomet has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Zimmer Biomet has recently decreased by 16.52%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Zimmer Biomet has a dividend yield of 0.95%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Zimmer Biomet does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Zimmer Biomet is 23.36%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Zimmer Biomet will have a dividend payout ratio of 10.82% next year. This indicates that Zimmer Biomet will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 3.7 / 5
• Environmental Score: -1.33

Percentage of Shares Shorted

2.94% of the float of Zimmer Biomet has been sold short.

Short Interest Ratio / Days to Cover

Zimmer Biomet has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Zimmer Biomet has recently decreased by 16.52%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.03

News Sentiment

Zimmer Biomet has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Zimmer Biomet this week, compared to 18 articles on an average week.

Search Interest

Only 5 people have searched for ZBH on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

7 people have added Zimmer Biomet to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Zimmer Biomet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $156,225.00 in company stock.

Percentage Held by Insiders

Only 0.70% of the stock of Zimmer Biomet is held by insiders.

Percentage Held by Institutions

88.89% of the stock of Zimmer Biomet is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ZBH Stock Analysis - Frequently Asked Questions

How have ZBH shares performed this year?

Zimmer Biomet's stock was trading at $105.63 on January 1st, 2025. Since then, ZBH stock has decreased by 5.0% and is now trading at $100.3060.

How were Zimmer Biomet's earnings last quarter?

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) released its earnings results on Thursday, August, 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.09. The business's quarterly revenue was up 7.0% on a year-over-year basis.
Read the conference call transcript.

Does Zimmer Biomet have any subsidiaries?

Zimmer Biomet subsidiaries include these companies: Respondwell, Clinical Graphics, CD Diagnostics, Medtech SAS, Compression Therapy Products, LDR Holding, Cayenne Medical, and more.

Who are Zimmer Biomet's major shareholders?

Top institutional investors of Zimmer Biomet include Vanguard Group Inc. (11.74%), Dodge & Cox (11.15%), State Street Corp (4.42%) and American Century Companies Inc. (2.88%). Insiders that own company stock include Chad F Phipps, Sang Yi, Lori Winkler, Robert Hagemann, Michael W Michelson, Sreelakshmi Kolli and Betsy J Bernard.
View institutional ownership trends.

How do I buy shares of Zimmer Biomet?

Shares of ZBH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Zimmer Biomet own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zimmer Biomet investors own include Chevron (CVX), Bristol Myers Squibb (BMY), Comcast (CMCSA), McKesson (MCK), Charles Schwab (SCHW), Edwards Lifesciences (EW) and Yum! Brands (YUM).

Company Calendar

• Record date for 7/31 Dividend: 6/26/2025
• Ex-Dividend for 7/31 Dividend: 6/26/2025
• Dividend Payable: 7/31/2025
• Last Earnings: 8/07/2025
• Today: 9/17/2025
• Record date for 10/31 Dividend: 9/30/2025
• Ex-Dividend for 10/31 Dividend: 9/30/2025
• Next Earnings (Estimated): 10/29/2025
• Dividend Payable: 10/31/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:ZBH
• Previous Symbol: NYSE:ZMH
• CIK: 1136869
• Web: www.zimmerbiomet.com
• Phone: (574) 267-6131
• Fax: 574-372-4988
• Employees: 17,000
• Year Founded: 1927

Price Target and Rating

• Average Price Target for Zimmer Biomet: $111.00
• High Price Target: $135.00
• Low Price Target: $95.00
• Potential Upside/Downside: +12.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.39
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.11
• Trailing P/E Ratio: 24.11
• Forward P/E Ratio: 12.05
• P/E Growth: 2.32
• Net Income: $903.70 million
• Net Margins: 10.51%
• Pretax Margin: 12.42%
• Return on Equity: 12.76%
• Return on Assets: 7.21%

Debt

• Debt-to-Equity Ratio: 0.54
• Current Ratio: 1.87
• Quick Ratio: 0.96

Sales & Book Value

• Annual Sales: $7.68 billion
• Price / Sales: 2.56
• Cash Flow: $12.95 per share
• Price / Cash Flow: 7.65
• Book Value: $62.67 per share
• Price / Book: 1.58

Miscellaneous

• Outstanding Shares: 198,100,000
• Free Float: 196,709,000
• Market Cap: $19.63 billion
• Optionable: Optionable
• Beta: 0.68